Lumera Corporation (LMRA)

[Orvis]

Lumera Reports Second Quarter 2008 Results, Confirms Progress on Proposed Merger
Monday August 4, 4:30 pm ET


BOTHELL, Wash.--(BUSINESS WIRE)--Lumera Corporation (NASDAQ:LMRA - News), a leader in photonics communication, today reported financial results for the second quarter 2008.
ADVERTISEMENT


Revenues totaled $1,499,000 for the three months that ended June 30, 2008 compared to $934,000 for the same period in 2007, reflecting an increase of 60%. Lumera’s loss from continuing operations totaled $1,649,000 or $0.08 per share for the second quarter of 2008 compared with a loss from continuing operations of $2,188,000 or $0.11 per share for the same period in 2007.

Revenues totaled $1,983,000 for the six months ended June 30, 2008 compared to $1,794,000 for the same period in 2007, reflecting an increase of 11%. Lumera’s loss from continuing operations totaled $5,226,000 or $0.26 per share for the six months of 2008 compared with a loss from continuing operations of $3,909,000 or $0.19 per share for the same period in 2007.

“We are pleased with our results this quarter," said Dr. Joe Vallner, Interim Chief Executive Officer of Lumera. “We have the highest level of government contract revenue commitments in our history which, as expected, will drive increasing contract revenues for us this year. Achieving our Telcordia testing milestones validates for us that our materials and devices can meet tough industry standards. Our restructuring efforts are bearing fruit, allowing us to focus singularly on our electro-optic business opportunities, and we’ve made good headway reducing embedded operating costs. We expect to see more of the same in the coming quarter leading up to our proposed merger.”

Lumera’s electro-optic business unit is developing a new generation of electro-optic modulators and other devices for optical networks and systems based on proprietary polymer materials.

During the quarter, Lumera announced that it had successfully completed its Telcordia standard reliability testing of its packaged polymer-based electro-optic modulators. Achieving these positive test results for the modulators demonstrates the viability of Lumera’s electro-optic polymer technology for component fabrication and validates the assertion that polymer modulators can pass the same rigorous tests required of industry standard components. Lumera is now in a position to share its internal reliability test results with potential customers and business partners.

The company also recently announced that it had completed a device shipment to Lockheed Martin in conjunction with a third order placed under the Material Transfer Agreement signed with Lockheed Martin in the first quarter 2008. This recent shipment evidences that Lumera’s relationship with Lockheed is continuing and expanding beyond electro-optic materials into prototype devices.

Proposed Merger with GigOptix, LLC

On March 27, 2008, Lumera Corporation and GigOptix, LLC (“GigOptix”) announced their entry into a definitive agreement to merge the two companies. Upon completion of the merger, which is subject to Lumera shareholder and other regulatory approval, existing securities holders of Lumera and GigOptix will each own approximately 50% of the outstanding securities of a new holding company named “GigOptix, Inc.” which will trade on the NASDAQ Market under the ticker symbol “GIGX.”

Lumera also recently announced that the Company had entered into definitive agreements with selected institutional investors to sell 4 million shares of its common stock and warrants to purchase an additional 2 million shares through a registered direct offering for net proceeds of approximately $2.8 million, after deducting offering fees and expenses. With the net proceeds from this offering, which was completed on July 16, 2008, we have met the minimum capital requirements closing condition in the GigOptix merger agreement.

Activities associated with our proposed merger with GigOptix continue to progress, albeit on a delayed schedule, due to a longer than expected period to produce audited GAAP financial statements at GigOptix. Information pertaining to the proposed merger, audited historical results for GigOptix LLC, and pro forma financial statements of the combined businesses will become available when an initial Registration Statement on Form S-4 is filed with the SEC. Due to the time required to produce the GigOptix financial statements, we currently expect to file the S-4 prior to the end of the third quarter. At that time, we anticipate holding a joint conference call to introduce Dr. Avi Katz and to discuss the proposed merger with GigOptix.

[KyInvestor]

Its on the move! News out on Lockhead Martin

[karizmat]

way undervalued. Could see8$ + soon.

[Orvis]

deleted

[lexi2004]

LMRA...I just posted this on a BB at SI....

To: TATRADER who wrote (58755) 6/5/2007 6:00:25 PM
From: lexi2004 of 58774

Mark...Found something interesting regarding LMRA.

One of LMRA's board members is also on the United States Air Force Scientific Advisory Board, and this is what they do:
Provide independent wisdom and insight to Air Force senior leaders on science and technology for continued air and space dominance.

So, never hurts to have good associations and believe this contact with senior Air Force leaders can only be a help to LMRA.

Lexi

[shmoopy38]

Alert Triggered for Lumera Corp
Lumera Corp (LMRA) Price Crossed Above Its 60 Day Moving Average

LMRA crossed above its 60 day moving average of $4.63 with a trade of $5.25 at 9:31 AM EDT, up 11.5% from the moving average. It is currently trading strongly higher on the day, up 1.6% to $5.15, on volume of 363,499, which is especially heavy given that there are still several hours left in the trading day.

Please note you will receive only one "Price Crosses its Moving Average" alert per day per stock which means that you will not get another 60 day moving average alert for LMRA.

[shmoopy38]

Lumera Corporation Announces Order from Fujitsu Labs of America

BOTHELL, Wash.--(BUSINESS WIRE)--May 23, 2007--Lumera Corporation (NASDAQ:LMRA), a leader in the emerging field of nanotechnology, today announced a purchase order from Fujitsu Laboratories of America (FLA), at www.fla.fujitsu.com, for its electro-optic polymer modulators.

"We have been working with FLA in the field of optical interconnects, creating polymer modulator arrays that can work at data rates of 10 Gbps," said Dr. Raluca Dinu, Director of Lumera's Electro-Optic Business Unit. "We look forward to an ongoing relationship with them as they continue to develop innovative circuit board solutions."

FLA is performing research activity in the areas of optical interconnect development. In testing polymer optical modulators FLA found Lumera's electro-optical polymer modulators offered high data rate connections. Fujitsu Limited has patent applications for a module or subsystem using a polymer modulator in such module or subsystem.

About Lumera

Lumera is a leader in the emerging field of nanotechnology. The company designs proprietary molecular structures and polymer compounds for the bioscience and communications/computing industries, both of which represent large market opportunities. The company also has developed proprietary processes for fabricating such devices. For more information, please visit www.lumera.com.

Certain statements contained in this release are forward-looking statements that involve a number of risks and uncertainties. Factors that could cause actual results to differ materially from those projected in the company's forward-looking statements include the following: market acceptance of our technologies and products; our ability to obtain financing; our financial and technical resources relative to those of our competitors; our ability to keep up with rapid technological change; government regulation of our technologies; our ability to enforce our intellectual property rights and protect our proprietary technologies; the ability to obtain additional contract awards and to develop partnership opportunities; the timing of commercial product launches; the ability to achieve key technical milestones in key products; and other risk factors identified from time to time in the company's SEC reports, including its Annual Report on Form 10-K, and its Quarterly Reports on Form 10-Q.


CONTACT: Investor Relations:
Lumera Corporation
Helene F. Jaillet, 425-398-6546
or
Media:
The Summit Group Communications
Todd Wolfenbarger, 801-595-1155
Cell: 801-244-9600

SOURCE: Lumera Corporation

[shmoopy38]

Alert Triggered for Lumera Corp
LMRA's Trading Volume Exceeded Daily Average by 201.6%

LMRA is up $0.47 or 11.14% to $4.69 on heavy volume that exceeded its daily average by 201.6%. This performance is better than the broader averages as the S&P 500 is up 0.49% on the day.

Please note you will receive only one "Trading Volume Exceeds Daily Average" alert per day for Lumera Corp.

[shmoopy38]

Lumera Reports First Quarter 2007 Results and Updates on Product Development Progress

BOTHELL, Wash., May 03, 2007 (BUSINESS WIRE) -- Lumera Corporation (NASDAQ: LMRA), a leader in the emerging field of nanotechnology, today reported financial results for the first quarter 2007 and released information regarding its current product development progress.

Revenues totaled $860,000 for the three months ended March 31, 2007 compared with $503,000 for the same period in 2006, a 71 percent increase over the prior year. Lumera's net loss totaled $2,696,000 or $0.13 per share for the three months ended March 31, 2007 compared with $3,120,000 or $0.19 per share for the same period in 2006.

"Lumera's first quarter is an indication of our continued progress forward," said Lumera Chief Executive Officer Tom Mino. "Increased revenue from government contracts resulted in the improved financial performance from a year ago. We've also entered into agreements in both business units that will enable us to continue building on our progress."

Summary Discussion of Product Development

Lumera develops proprietary polymer materials which are used in bioscience products and in electro-optic devices further detailed in the market summaries below.

Bioscience

Lumera is developing label free high throughput methods targeted at the biological and medical research markets.

Early in the quarter, Lumera announced that Dr. Josh LaBaer of the Harvard Institute of Proteomics presented his early research results using the ProteomicProcessor(TM) at the PEPTalk meeting in San Diego. Dr. LaBaer reported the successful integration of Harvard's NAPPA protein array methodology on Lumera's chip surface and, together, Lumera and Dr. LaBaer's group are working on building an array of kinase proteins.

Also during the quarter, the Company announced an important application for its ProteomicProcessor(TM) developed by the Institute for Systems Biology. The application allowed researchers to identify a novel biomarker panel associated with liver toxicity in mice. This development potentially opens a new avenue demonstrating how the instrument could be used in biomarker discovery.

Electro-Optics

Lumera is developing a new generation of electro-optic modulators and other devices for optical networks and systems based on proprietary polymer materials.

During the quarter, the Company announced it had received a purchase order from Lockheed Martin and entered into an agreement with Lockheed for Lumera's high electro-optic activity materials. The term of the agreement ends December 31, 2007, at which time Lockheed Martin will advise Lumera of its intentions regarding a commercial license for the materials.

Also during the quarter, Lumera announced that it had been awarded an extension to a U.S. government contract to continue development of technologically advanced wideband optical modulators. The twelve month contract is valued at approximately $1.15 million. The overall contract value has now reached approximately $6.9 million.

Summary Financial Discussion

Revenues totaled $860,000 for the three months ended March 31, 2007 compared with $503,000 for the same period in 2006, a 71 percent increase over the prior year. Government contract revenue totaled $775,000 for the current quarter, in increase of $292,000 from $483,000 in 2006 due primarily to higher billings on two of our contracts.

Product revenues totaled $85,000 for the current quarter, reflecting sales of electro-optic modulators. Backlog on our government contracts totaled $2,048,000 at March 31, 2007.

Operating expenses for the three months ended March 31, 2007, decreased by $139,000 to $3,434,000 compared to $3,573,000 for the same period in 2006. Research and Development expense, which totaled $1,271,000 for the three months ended March 31, 2007, decreased by $307,000, or 19 percent, from $1,578,000 for the same period in 2006 due to increased government contract activities resulting in higher levels of labor and related overhead costs being allocated to the cost of contract revenues and lower depreciation costs as our asset base becomes more fully depreciated. Marketing, general and administrative expense, which totaled $2,163,000 for the three months ended March 31, 2007, increased by $168,000, or 8 percent, from the same period in 2006 due primarily to cash compensation costs associated with additional sales and marketing and administrative personnel and increased consulting fees.

Lumera's net loss totaled $2,696,000 or $0.13 per share for the three months ended March 31, 2007, compared with $3,120,000, or $0.19 per share for the same period in 2006.

Lumera, which ended the quarter with $24.1 million in cash and investment securities, used $2.2 million in cash to fund operations and working capital requirements during the three months ended March 31, 2007, a decrease of $605,000 over the same period in 2006. Capital expenditures, which include leasehold and related capital improvements, totaled $71,000 for the first quarter of 2007, down from $317,000 during the same period in 2006.

Conference Call

Lumera will host a conference call to discuss its third quarter of 2006 financial results on Thursday, May 3 at 4:30 p.m. EDT. The call will be broadcast over the Internet and can be accessed from the company's web site at www.lumera.com. Additionally, U.S. participants may join the conference call by dialing 800.638.4817 ten minutes prior to the start of the conference. International participants can dial 617.614.3943. The conference passcode number is 23714654. A telephone replay of the call will be available through May 10, and can be accessed by dialing 888-286-8010 (for U.S. participants) or 617-801-6888 (for international participants). The replay passcode is 32065724. A replay of the conference call will be available on the company's web site.

About Lumera

Lumera is a leader in the emerging field of nanotechnology. The company designs proprietary molecular structures and polymer compounds for the bioscience and communications industries, both of which represent large market opportunities. The company also has developed proprietary processes for fabricating such devices. For more information, please visit www.lumera.com.

Certain statements contained in this release are forward-looking statements that involve a number of risks and uncertainties. Factors that could cause actual results to differ materially from those projected in the company's forward-looking statements include the following: market acceptance of our technologies and products; our ability to obtain financing; our financial and technical resources relative to those of our competitors; our ability to keep up with rapid technological change; government regulation of our technologies; our ability to enforce our intellectual property rights and protect our proprietary technologies; the ability to obtain additional contract awards and to develop partnership opportunities; the timing of commercial product launches; the ability to achieve key technical milestones in key products; and other risk factors identified from time to time in the company's SEC reports, including its Annual Report on Form 10-K, and its Quarterly Reports on Form 10-Q.

Lumera Corporation
Condensed Balance Sheets
(In thousands)
(Unaudited)

March 31, December 31,
Assets 2007 2006
------------ -------------
Current assets
Cash and cash equivalents $ 5,443 $ 10,521
Investment securities, available-for-
sale 18,659 15,788
Accounts Receivable, net of allowance 5 380
Costs and estimated earnings in excess
of billings on uncompleted contracts 380 338
Other current assets 462 600
------------ -------------
Total current assets 24,949 27,627

Property and equipment, net 2,612 2,759
Restricted Investments 700 700
Other Assets 46 46
------------ -------------
Total assets $ 28,307 $ 31,132
============ =============


Liabilities and Shareholders' equity

Current liabilities
Accounts payable $ 398 $ 850
Accrued liabilities 891 982
------------ -------------
Total current liabilities 1,289 1,832

Deferred rent, net of current portion 385 407
------------ -------------
Total current liabilities 1,674 2,239

Commitments and contingencies

Shareholders' equity
Common stock at par value 20 20
Additional paid-in capital 90,125 89,690
Accumulated other comprehensive loss 2 1
Accumulated deficit (63,514) (60,818)
------------ -------------
Total shareholders' equity 26,633 28,893
------------ -------------
Total liabilities and shareholders' equity $ 28,307 $ 31,132
============ =============


Statements of Operations
(In thousands, except earnings per share and share data)
(Unaudited)

Three months ended March 31,
----------------------------
2007 2006
-------------- -------------

Revenue $ 860 $ 503
Cost of revenue 443 258
-------------- -------------
Gross profit 417 245
-------------- -------------

Research and development expense 1,271 1,578
Marketing, general and administrative
expense 2,163 1,995
-------------- -------------
Total operating expenses 3,434 3,573
-------------- -------------

Loss from operations (3,017) (3,328)
Interest income 321 208
-------------- -------------
Net loss from operations $ (2,696) $ (3,120)
============== =============

Net loss per share-basic and diluted $ (0.13) $ (0.19)
============== =============

Weighted-average shares outstanding -
basic and diluted 20,055,352 16,757,005
============== =============


SOURCE: Lumera Corporation

Lumera Corporation
Helene F. Jaillet, 425-398-6546 (Investor Relations)
or
The Summit Group Communications
Todd Wolfenbarger, 801-595-1155 (Media)
801-244-9600 cell

[shmoopy38]

Lumera Extends Collaborative Research Agreement with the Institute for Systems Biology

Collaboration to Focus on Predictive Biomarkers for both Drug
Toxicity and Cancer

BOTHELL, Wash.--(BUSINESS WIRE)--May 2, 2007--Lumera Corporation (NASDAQ:LMRA), a leader in the emerging field of nanotechnology, announced today that it has extended its collaboration agreement with the Institute for Systems Biology (ISB). The goal of the collaboration is to use Lumera's ProteomicProcessor(TM) to identify biomarkers associated with drug toxicity and cancer.

As previously announced, ISB researchers have demonstrated a label-free assay to determine protein expression patterns using a panel of specific antibodies printed on Lumera's NanoCapture-Gold(TM) microarray and analyzed on the company's ProteomicProcessor (TM) instrument system.

"We are quite pleased with the progress of the past year," said Dr. Leroy Hood, President of the Institute for Systems Biology. "Lumera's platform provides unique advantages in biomarker discovery and we are committed to moving the science forward."

"Early results from ISB have been proof positive that our technology adds significant value to the biomarker discovery market. We feel that with a continued emphasis on this project, we will arrive at a very important publication and will establish methods by which others will be able to develop their own assays," said Dr. Timothy Londergan, Lumera's Bioscience Business Unit.

As previously discussed by the company, biomarkers are important indicators of disease and their identification can lead to the development of targeted drug solutions to prevent or arrest the disease. Biomarker screening has been an increasing area of research growing from $5.4 billion in 2005 to an estimated $21 billion by 2012 according to Business Insights, a market research firm.

About Lumera

Lumera is an emerging leader in the field of nanotechnology. The company designs proprietary molecular structures and polymer compounds for a broad range of bioscience, electro-optic, and specialty nanotechnology applications. The company also has developed proprietary processes for fabricating such devices. For more information, please visit http://www.lumera.com/.

Certain statements contained in this release are forward-looking statements that involve a number of risks and uncertainties. Factors that could cause actual results to differ materially from those projected in the company's forward-looking statements include the following: market acceptance of our technologies and products; our ability to obtain financing; our financial and technical resources relative to those of our competitors; our ability to keep up with rapid technological change; government regulation of our technologies; our ability to enforce our intellectual property rights and protect our proprietary technologies; the ability to obtain additional contract awards and to develop partnership opportunities; the timing of commercial product launches; the ability to achieve key technical milestones in key products; and other risk factors identified from time to time in the company's SEC reports, including in its registrations statement on Form S-1, dated July 22, 2004 and its Quarterly Reports on Form 10-Q.


CONTACT: The Summit Group Communications
Todd Wolfenbarger, 801-595-1155
801-244-9600 cell

SOURCE: Lumera Corporation

[shmoopy38]

InPlay 8:51AM - Lumera and MUSC to develop antibody array for protein expression profiling (LMRA) 4.64 : Co announces that it has extended its collaboration agreement with the Medical University of South Carolina. In partnership with Lumera scientists, M.U.S.C researchers intend to develop an antibody array that will measure the levels and modifications of patient mitochondrial proteins. Under the agreement, Lumera will retain rights to commercialize all jointly developed intellectual property.

[shmoopy38]

Alert Triggered for Lumera Corp.
LMRA's Trading Volume Exceeded Daily Average by 201.4%

LMRA is up $0.14 or 2.74% to $5.25 on heavy volume that exceeded its daily average by 201.4%. This performance is in-line-with the broader averages as the S&P 500 is down 0.05% on the day.

Please note you will receive only one "Trading Volume Exceeds Daily Average" alert per day for Lumera Corp.

[shmoopy38]

Alert Triggered for Lumera Corp.
LMRA's Trading Volume Exceeded Daily Average by 208.5%
March 28, 2007

LMRA is up $0.50 or 10.53% to $5.25 on heavy volume that exceeded its daily average by 208.5%. This performance is better than the broader averages as the S&P 500 is down 0.47% on the day.

Please note you will receive only one "Trading Volume Exceeds Daily Average" alert per day for Lumera Corp.

[shmoopy38]

Alert Triggered for Lumera Corp.
Lumera Corp. (LMRA) Price Crossed Above Its 60 Day Moving Average

LMRA crossed above its 60 day moving average of $4.70 by a fraction of a penny. Although it is still strongly higher on the day, it is now trading at $4.69 which is below the moving average.

Please note you will receive only one "Price Crosses its Moving Average" alert per day per stock which means that you will not get another 60 day moving average alert for LMRA.

[shmoopy38]

Emerging Stock Report! March 28, 2007
NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by Stock Market Alerts.

MIAMI, FL -- (MARKET WIRE) -- March 28, 2007 -- Stock Market Alerts' performance stock list includes: Aegis Industries Incorporated (OTCBB: AGIN), Apple, Inc. (NASDAQ: AAPL), Oracle (NASDAQ: ORCL), Lumera Corp. (NASDAQ: LMRA).

Lumera Corporation (NASDAQ: LMRA) up 9.9% on 1 million shares traded. Lumera is a leader in the emerging field of nanotechnology. The company designs proprietary molecular structures and polymer compounds for the bioscience and communications/computing industries, both of which represent large market opportunities.

[shmoopy38]

LMRA in TWST:

http://media.corporate-ir.net/media_files/IROL/18/181846/presentations/TWST_interview_0212.pdf

[shmoopy38]

Lumera Secures Million-Dollar Contract for Wideband Optical Modulators
Tuesday March 20, 9:00 am ET

BOTHELL, Wash.--(BUSINESS WIRE)--Lumera Corporation (NASDAQ:LMRA - News), a leader in the emerging field of nanotechnology, announced today that it has been awarded an extension to a U.S. government contract to continue development of technologically advanced wideband optical modulators. The 12-month contract is valued at approximately $1.15 million; the overall contract value has now reached approximately $6.9 million.

"This is further validation of the superiority of our electro-optic devices and materials and, along with other Lumera government contracts, directly parallels our roadmap to commercial products," said Tom Mino, Chief Executive Officer of Lumera. "Being chosen is recognition of our performance in meeting the technical and financial milestones defined in the contracts."

Lumera is developing high-performance modulators which enable a new generation of fiber-optic systems that are expected to deliver increased bandwidth at competitive costs and use lower power than current devices.

About Lumera

Lumera is a leader in the emerging field of nanotechnology. The company designs proprietary molecular structures and polymer compounds for the bioscience and communications/computing industries, both of which represent large market opportunities. The company also has developed proprietary processes for fabricating such devices. For more information, please visit www.lumera.com.

Certain statements contained in this release are forward-looking statements that involve a number of risks and uncertainties. Factors that could cause actual results to differ materially from those projected in the company's forward-looking statements include the following: market acceptance of our technologies and products; our ability to obtain financing; our financial and technical resources relative to those of our competitors; our ability to keep up with rapid technological change; government regulation of our technologies; our ability to enforce our intellectual property rights and protect our proprietary technologies; the ability to obtain additional contract awards and to develop partnership opportunities; the timing of commercial product launches; the ability to achieve key technical milestones in key products; and other risk factors identified from time to time in the company's SEC reports, including its Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q.

Contact:
Lumera Corporation
Helene Jaillet, 425-398-6546
[e-mail]
or
The Summit Group Communications
Todd Wolfenbarger, 801-595-1155
801-244-9600 cell

--------------------------------------------------------------------------------
Source: Lumera Corporation

[shmoopy38]

Lumera Corporation to Exhibit at OFC/NFOEC in Anaheim
BusinessWire - March 16, 2007 9:00 AM ET

Lumera Corporation (NASDAQ:LMRA), a leader in the emerging field of nanotechnology, announced today that it will be exhibiting at the Optical Fiber Communication Conference & Exposition and the National Fiber Optic Engineers Conference (OFC/NFOEC). The conference being held in Anaheim, California, begins on Sunday, March 25, 2007, and continues through Thursday, March 29, 2007. The conference is expected to draw 13,000 attendees from commercial, government, and research institutions. It is the premier international event for both the science and business of optical communications.

About Lumera

Lumera is a leader in the emerging field of nanotechnology. The company designs proprietary molecular structures and polymer compounds for the bioscience and communications/computing industries, both of which represent large market opportunities. The company also has developed proprietary processes for fabricating such devices. For more information, please visit www.lumera.com.

Certain statements contained in this release are forward-looking statements that involve a number of risks and uncertainties. Factors that could cause actual results to differ materially from those projected in the company's forward-looking statements include the following: market acceptance of our technologies and products; our ability to obtain financing; our financial and technical resources relative to those of our competitors; our ability to keep up with rapid technological change; government regulation of our technologies; our ability to enforce our intellectual property rights and protect our proprietary technologies; the ability to obtain additional contract awards and to develop partnership opportunities; the timing of commercial product launches; the ability to achieve key technical milestones in key products; and other risk factors identified from time to time in the company's SEC reports, including its Annual Report on Form 10-K, and its Quarterly Reports on Form 10-Q.

SOURCE: Lumera Corporation

The Summit Group Communications
Todd Wolfenbarger, 801-595-1155
Cell: 801-244-9600

[shmoopy38]

Alert Triggered for Lumera Corp.
Lumera Corp. (LMRA) Price Crossed Above Its 60 Day Moving Average

LMRA crossed above its 60 day moving average of $5.03 with a trade of $5.09 at 9:30 AM EDT, up 36.7% from the moving average. Although it is still higher on the day, it is now trading at $4.99 which is below the moving average.

Please note you will receive only one "Price Crosses its Moving Average" alert per day per stock which means that you will not get another 60 day moving average alert for LMRA.

[shmoopy38]

Lumera Receives Order and Enters Into Agreement with Lockheed Martin
Monday March 12, 8:45 am ET

BOTHELL, Wash.--(BUSINESS WIRE)--Lumera Corporation (NASDAQ:LMRA - News), a leader in the emerging field of nanotechnology, announced today that it had received a purchase order from Lockheed Martin for Lumera's high electro-optic activity materials. The term of the agreement is until December 31, 2007, at which time Lockheed Martin will advise Lumera of its intentions regarding a commercial license for the materials.

"We are pleased that Lockheed Martin is interested in our polymer materials and expect that the materials will perform as anticipated," said Dr. Raluca Dinu, Director of Lumera's Electro-Optic Business Unit. "We look forward to developing a long-term relationship with Lockheed Martin."

About Lumera

Lumera is a leader in the emerging field of nanotechnology. The company designs proprietary molecular structures and polymer compounds for the bioscience and communications/computing industries, both of which represent large market opportunities. The company also has developed proprietary processes for fabricating such devices. For more information, please visit www.lumera.com.

Certain statements contained in this release are forward-looking statements that involve a number of risks and uncertainties. Factors that could cause actual results to differ materially from those projected in the company's forward-looking statements include the following: market acceptance of our technologies and products; our ability to obtain financing; our financial and technical resources relative to those of our competitors; our ability to keep up with rapid technological change; government regulation of our technologies; our ability to enforce our intellectual property rights and protect our proprietary technologies; the ability to obtain additional contract awards and to develop partnership opportunities; the timing of commercial product launches; the ability to achieve key technical milestones in key products; and other risk factors identified from time to time in the company's SEC reports, including its Annual Report on Form 10-K, and its Quarterly Reports on Form 10-Q.



Contact:
The Summit Group Communications
Todd Wolfenbarger, 801-595-1155
801-244-9600 cell

--------------------------------------------------------------------------------
Source: Lumera Corporation

[shmoopy38]

Lumera Corporation To Hold Conference Call To Discuss Q4 2006 Results
Thursday February 22, 2:40 pm ET

BOTHELL, Wash.--(BUSINESS WIRE)--Lumera Corporation (NASDAQ:LMRA - News), an emerging leader in the field of nanotechnology, will hold its quarterly conference call to discuss fourth quarter 2006 results on March 8, 2007 at 4:30PM Eastern Standard Time (1:30PM Pacific Standard Time).

Details to access the conference call and the live audio web cast are as follows:

Conference call

(Please call approximately ten minutes prior to the scheduled start of the call)

Toll-free: 866.825.1709

International callers: 617.213.8060

Pass code: 39340297

Live Audio web cast: www.Lumera.com

Replay and archive information:

(Telephone replay available until March 15, 2007 6:30 PM)

Toll-free: 888-286-8010

International callers: 617-801-6888

Pass code: 49339768

Web cast will be archived on the Company's website at www.Lumera.com

About Lumera

Lumera is a leader in the emerging field of nanotechnology. The company designs proprietary molecular structures and polymer compounds for the bioscience and communications/computing industries, both of which represent large market opportunities. The company also has developed proprietary processes for fabricating such devices. For more information, please visit www.lumera.com.

Contact:
Lumera Corporation
Helene F. Jaillet (Investor Relations), 425-398-6546
or
The Summit Group Communications
Todd Wolfenbarger (Media), 801-595-1155
http://www.lumera.com

--------------------------------------------------------------------------------
Source: Lumera Corporation

[shmoopy38]

Alert Triggered for Lumera Corp
Lumera Corp (LMRA) Price Crossed Above Its 60 Day Moving Average

LMRA crossed above its 60 day moving average of $5.70 with a trade of $5.74 at 12:57 PM EST, up 9.0% from the moving average. It is currently trading strongly higher on the day, up 10.9% to $5.71.

[shmoopy38]

Alert Triggered for Lumera Corp
LMRA's Trading Volume Exceeded Daily Average by 200.4%

LMRA is up $0.21 or 4.14% to $5.31 on heavy volume that exceeded its daily average by 200.4%. This performance is better than the broader averages as the S&P 500 is down 0.11% on the day.

[shmoopy38]

Lumera Ready to Pop
Source: www.antandsons.com
February 13, 2007

Lumera Corp. (NASDAQ: LMRA) has attracted a lot of bottom fishers hoping that the stock would gain some traction to the upside after basing above the $4 level since early February. Lumera was first put on the radar in October of last year when it announced that it completed successful testing of its millimeter wave wireless bridge. Lumera said the system will allow the transmission of "vast amounts of data via a variety of high speed telecommunications networks." Yet, shares just went ice cold, peaking after November earnings news in which the company reported losses for the third quarter and announced a $17 million private placement.

In December, the company updated investors on its wireless bridge, saying that it successfully tested data rates from 2.5 gigabits per second (Gbps) to 10 Gbps and is still trying to create a commercial-ready product. Lumera is also working with Harvard Medical School researchers to build discovery and diagnostic methods with Lumera's Proteomic Processor biosensor relevant to cancer research. More recently, the company announced in January that it was showcasing the new design of its ProteomicProcessor at PepTalk, a week long conference on protein research being held in San Diego. According to Lumera officials, the new design is the result of feedback from drug discovery scientists at several biopharmaceutical companies with whom the company has ongoing discussions.

Could Lumera perhaps strike a partnership with these companies? It is a possibility, but the company has been real quiet. Certainly, though, any update on their research and development activities would likely go a long way in spurring shares that have not seen a lot of interest lately. A move in share price is also likely to be amplified by the massive short position in Lumera shares. Current data shows there are about 3.37 million shares short, nearly 35% of the company's public float of 9.48 million shares. Perhaps that is why there has been a few spikes higher this week as short sellers begin to cover their positions before there is any impetus to push the stock higher.

[shmoopy38]

Alert Triggered for Lumera Corp
Lumera Corp (LMRA) Price Increased 14.19% from Wednesday's Close

LMRA increased 14.19% today and is currently trading at $5.07.

[MMKILLA]

LMRA reversal coming double doji with good volume and looks like it has strogn support at the 200MA

[shmoopy38]

Lumera Showcases New Design of ProteomicProcessor(TM) at PepTalk -- Sponsors Workshop for Dr. Joshua LaBaer of Harvard Institute for Proteomics --
Thursday January 4, 9:00 am ET

BOTHELL, Wash.--(BUSINESS WIRE)--Lumera Corporation (NASDAQ: LMRA - News), an emerging leader in the field of nanotechnology, announced today it will be showcasing the new design of its ProteomicProcessor(TM) at PepTalk, a week long conference on protein research being held in San Diego from January 8 - 12, 2007. The company is also sponsoring a luncheon workshop at the conference for Dr. Joshua LaBaer of the Harvard Institute of Proteomics, in which he will discuss his research using Lumera's ProteomicProcessor(TM).

"The new design is the result of feedback from drug discovery scientists at several biopharmaceutical companies with whom we have ongoing discussions," said Ron Dudek, Lumera Business Development Director. "The input we've received from the field has allowed us to incorporate important features that we believe will meet customer expectations."

Harvard's Dr. LaBaer is a well-known researcher in the field of proteomics. He recently discussed his research in an article in the December 14 issue of Nature Magazine (http://www.nature.com/nature/journal/v444/n7121/index.html). Lumera executives were also interviewed in the article.

"Josh LaBaer is a giant in his field and we're very pleased to sponsor the luncheon workshop at PepTalk. We look forward to continuing our collaboration with him on the protein research he's been developing," said Dr. Tim Londergan, Director of Lumera's Bioscience Business Unit.

About Lumera

Lumera is a leader in the emerging field of nanotechnology. The company designs proprietary molecular structures and polymer compounds for the bioscience and communications/computing industries, both of which represent large market opportunities. The company also has developed proprietary processes for fabricating such devices. For more information, please visit www.lumera.com.

Certain statements contained in this release are forward-looking statements that involve a number of risks and uncertainties. Factors that could cause actual results to differ materially from those projected in the company's forward-looking statements include the following: market acceptance of our technologies and products; our ability to obtain financing; our financial and technical resources relative to those of our competitors; our ability to keep up with rapid technological change; government regulation of our technologies; our ability to enforce our intellectual property rights and protect our proprietary technologies; the ability to obtain additional contract awards and to develop partnership opportunities; the timing of commercial product launches; the ability to achieve key technical milestones in key products; and other risk factors identified from time to time in the company's SEC reports, including its Annual Report on Form 10-K, and its Quarterly Reports on Form 10-Q.



Contact:
The Summit Group Communications
Todd Wolfenbarger, 801-595-1155
801-244-9600 (cell)

--------------------------------------------------------------------------------
Source: Lumera Corporation

[shmoopy38]

Los Alamos National Laboratory Completes Successful Analysis of Antibodies Using Lumera Corporation Technology
8:45 AM EST November 15, 2006

Lumera Corporation (Nasdaq:LMRA), an emerging leader in the field of nanotechnology, announced today that its proprietary Heterodimer Protein Technology (HPT) and ProteomicProcessor(TM) were both successfully used to analyze single chain antibodies from Los Alamos National Laboratory (LANL).

"Lumera is pleased to work with Los Alamos National Laboratory," said Tom Mino, Lumera CEO. "Our Bioscience Business Unit channels our nanotechnology platform into developing useful tools for finding and speeding up the delivery of the next billion-dollar therapeutic drug. This work illustrates the versatility of the Lumera antibody discovery products, which we plan to offer next year to the drug discovery market."

"Currently, we are using e-coil tagged, single chain antibodies in a high throughput flow cytometry-based screening and characterization," said Peter Pavlik, project leader at Los Alamos. "Having access to Lumera's high throughput SPR-based characterization technology that uses the same coil chemistry would increase our ability to characterize antibodies in great detail."

"The extraordinary revenue growth rate of therapeutic antibodies is one of the most attractive in the pharmaceutical industry," said Ronald Dudek, Director of Business Development at Lumera Corporation. "The Lumera antibody discovery products will be the first of a suite of new products that present a total solution to our partners in the drug discovery market. We believe that applied nanotechnology solutions, like those we will offer, will increase the speed and efficiency of pharmaceutical drug discovery."

Los Alamos National Laboratory is a world leader in phage display technology, antibody engineering, and the development of high throughput screening assays. Phage display is an emerging technology for the production of very large and highly diverse antibody libraries. Antibodies are the human body's immune response to infection, which is typically caused by foreign substances or antigens. Scientists have found that antibodies have the capacity to bind specifically to antigens, thereby neutralizing the antigen. This ability is giving rise to a very large pharmaceutical market known as therapeutic antibodies. Rituxan, a highly successful billion-dollar commercial drug which treats non-Hodgkin's lymphoma, is an example of a therapeutic antibody drug.

The LANL single chain antibodies were engineered to contain the Lumera E-Coil peptide tag. The engineered antibodies were then screened using the Lumera NanoCapture(TM) K-Coil microarray slide and ProteomicProcessor(TM) instrument system.

About Lumera

Lumera is a leader in the emerging field of nanotechnology. The company designs proprietary molecular structures and polymer compounds for the bioscience and communications/computing industries, both of which represent large market opportunities. The company also has developed proprietary processes for fabricating such devices. For more information, please visit www.lumera.com.

About Los Alamos National Laboratory

Los Alamos National Laboratory is a multidisciplinary research institution engaged in strategic science on behalf of national security. The Laboratory is operated by a team composed of Bechtel National, the University of California, BWX Technologies, and Washington Group International for the Department of Energy's National Nuclear Security Administration. Los Alamos enhances national security by ensuring the safety and reliability of the U.S. nuclear stockpile, developing technologies to reduce threats from weapons of mass destruction, and solving problems related to energy, environment, infrastructure, health and global security concerns.

Certain statements contained in this release are forward-looking statements that involve a number of risks and uncertainties. Factors that could cause actual results to differ materially from those projected in the company's forward-looking statements include the following: market acceptance of our technologies and products; our ability to obtain financing; our financial and technical resources relative to those of our competitors; our ability to keep up with rapid technological change; government regulation of our technologies; our ability to enforce our intellectual property rights and protect our proprietary technologies; the ability to obtain additional contract awards and to develop partnership opportunities; the timing of commercial product launches; the ability to achieve key technical milestones in key products; and other risk factors identified from time to time in the company's SEC reports, including its Annual Report on Form 10-K, and its Quarterly Reports on Form 10-Q.

SOURCE: Lumera Corporation

The Summit Group Communications Todd Wolfenbarger, 801-595-1155; 801-244-9600 (cell)

[eagle_2975]

that's all fun and cute...but that doesn't cover the fact that the MMW's commercial product won't be ready for about another 18 months(per LMRA's IR), they don't know how much it will sell for, or how big the market size is for the product. At the company's current burn rate, they will be lucky if they have enough cash to make it through to that point, let alone have enough cash to rev up sales and marketing =====> do you smell private placement soon???? I do, and a dump after the earnings report.

[kumqwatt]

LMRA running

[shmoopy38]

Latest Business Week from Yahoo MB: "One of the biggest winners on the NASDAQ in October was an obscure outfit called Lumera (LMRA ). It rocketed from 1.58 on Friday, Oct. 13, to 5 on Monday, Oct. 16. By Oct. 24, it had jumped to 7.56. It has since gone up to 8.08. Part of the lightning rise was due to short-covering. The big crowd that had shorted it didn't expect such a blitzkrieg in just days. Is Lumera a mere flash in the pan? Don't count it out, "as it is certainly a stock to watch," says Bernie Schaeffer, CEO of Schaeffer's Investment Research. Lumera started to move after the electronics specialist said it completed successful testing of its "millimeter wave wireless bridge" that allows the transmission of "vast amounts of data via a variety of high-speed telecommunications networks." According to co's CEO, the new system could download the data-equivalent of six DVDs in one minute. Lumera has also produced a "Proteomic Processor" biosensor that Harvard Medical School will use "to develop chemistry for drug discovery," says Mino. Short-covering, says Schaeffer, could fuel more rallies in the stock.

[IPRE-Paramount2]

The short Trigger is definitely ON, and no look back.
SEE you over 20 within 10 days then it will be a long years runner :)

[shmoopy38]

Lighting up Nanotechnology

Published in M2 PressWIRE on Tuesday, 31 October 2006 at 16:21 GMT
Copyright (C) 2006, M2 Communications Ltd.

Lumera (NASDAQ:LMRA) lights the way in the development of polymer materials and products based on those materials for use in wireless and optical communications networks and in biochemical analysis. Lumera develops custom electro-optic devices for the US government, particularly the Department of Defense, which accounts for nearly all of sales. Products in development include compact panel wireless antennas (AccuPath), disposable biochips used to isolate DNA and protein samples for testing (NanoCapture), and electro-optic modulators and optical interconnects for use in telecommunications applications.

Shares were up 13% since Harvard Medical School researchers started using Lumera's ProteomicProcessor Biosensor.

Bellwether Report is tracking Lumera Corp. for more information on the company, sign up to BellwetherReport.com for a complimentary subscription. To view the company press release continue below.

Lumera Corporation, an emerging leader in the field of nanotechnology, announced that Harvard Medical School researchers are now building next generation discovery and diagnostics methods with Lumera's ProteomicProcessor(TM) Biosensor.

During the past year, Lumera has placed four beta units with highly respected, world renowned research organizations to demonstrate and establish new applications that take advantage of the instrument's unprecedented throughput in a label-free format. Harvard has served as a beta site for Lumera's biosensor platform, the ProteomicProcessor(TM), since mid-2006. The Harvard collaboration is focused on integrating their NAPPA (Nucleic Acid Programmable Protein Array) technology, which provides a simple and cost-effective way to generate a protein biochip, with the ProteomicProcessor(TM) to read and analyze the biochip.

"In the past quarter, we have successfully narrowed the window of processing conditions to produce a ProteomicProcessor(TM) compatible NAPPA array," said Dr. Joshua LaBaer, Director of the Harvard Institute of Proteomics. "We now have a solid foundation on which to begin our development efforts. Among our first areas of investigation will be probing a family of 200 kinase proteins for their interaction with and among drug families relevant to cancer research." "There is a significant amount of value to the pharmaceutical development market in combining these two technologies," said Dr. Timothy Londergan, Director of Lumera's Bioscience Business. "This will ultimately lead to new products that take advantage of NAPPA's unique capability of producing proteins on demand and the ProteomicProcessor's unique ability to understand in great detail how the proteins are interacting with each other and with other compounds, like, for example, drug candidates. We are particularly interested in using NAPPA to generate a human protein kinase array, allowing us to address a very large and growing segment of the drug discovery market with a high value consumable product." According to Frost and Sullivan, the pharmaceutical industry spends nearly one third of its $50 billion of research and development dollars on kinase inhibitor therapeutics. Kinases are a class of proteins which are known to signal certain illnesses, including some cancers, to the "on" or diseased state. Kinase inhibitors effectively can turn the "on" signal to an "off" state. Interest in this area has been propelled by the success of Gleevec, a multibillion drug from Novartis which was the first approved drug to directly turn off the signal of a protein known to cause a cancer.

Bellwether Report is an online financial newsletter focused on researching small-cap and large-cap public companies. Information has been obtained from sources considered to be reliable, but we do not guarantee that it is accurate or complete. This material is not an offer to sell or a solicitation of an offer to buy any securities. BWR and its affiliates, officers, directors and agents have been compensated to perform research and therefore information should not be construed as unbiased. Each contract varies in duration, services performed and compensation received. BWR is not responsible for any claims made by the Company. You should independently investigate and fully understand all risks before investing. We are not a registered broker-dealer. Before investing in any securities, you should consult with your financial advisor and a registered broker-dealer. Our views and opinions regarding the Company are our own views and are based on information that we have received, which we assumed to be reliable. We do not guarantee that the Company will perform as we expect, and any comparisons we have made to other companies may not be valid or come into effect. Statements included may contain forward looking statements, including the Company's intentions, forecasts, plans or other matters that haven't yet occured. Such statements involve a number of risks and uncertainties. Further information on potential factors that may affect, delay or prevent such forward looking statements from coming to fruition can be found in their specific Financial reports, including the 10-K and 10-Q, which are filed with the Securities and Exchange Commission (SEC). Bellwether Report will receive 25% of all sales from the Bell Alerts services and will receive 66% of all sales of Research Reports.


Release date: 31 Oct 2006

[kumqwatt]

Still going up afterhours

[kumqwatt]

only 9M float

[shmoopy38]

InPlay
October 31, 2006
8:56AM Lumera: Harvard Medical School researchers to build next generation discovery and diagnostics methods with co's
ProteomicProcessor Biosensor (LMRA) 6.35 : Co announces that Harvard Medical School researchers are now building next generation discovery and diagnostics methods with it's ProteomicProcessor Biosensor. During the past year, Lumera has placed four beta units with highly respected, world renowned research organizations to demonstrate and establish new applications that take advantage of the instrument's unprecedented throughput in a label-free format. Harvard has served as a beta site for Lumera's biosensor platform, the ProteomicProcessor(TM), since mid-2006. The Harvard collaboration is focused on integrating their NAPPA (Nucleic Acid Programmable Protein Array) technology, which provides a simple and cost-effective way to generate a protein biochip, with the ProteomicProcessor(TM) to read and analyze the biochip.

[shmoopy38]

Update: Paulson Investment's 29th Annual Westergaard SmallCap Conference to Showcase Emerging Industry Leaders
Monday October 30, 2:25 pm ET

Hosted by Paulson Investment Company, Inc. and Dutton Associates, Event Scheduled for Monday, November 6, 2006 in New York City

NEW YORK, NY--(MARKET WIRE)--Oct 30, 2006 -- Paulson Investment Company, Inc., a wholly owned subsidiary of Paulson Capital Corp. ("Paulson") (NASDAQ:PLCC - News), and Dutton Associates today issued the following updates and finalized list of presenters for Paulson Investment's 29th Annual Westergaard SmallCap Conference.

The Conference will showcase small and emerging growth companies focused on establishing leadership in a broad range of industry sectors, including alternative energy, security, technology, pharmaceutical, biotechnology, environmental and consumer products. Founded in 1978 by noted small cap analyst John Westergaard, this conference provides a venue for select small cap companies to share detailed insight into their business operations, short and long term growth strategies, and industry vision.

Hundreds of investment professionals have already pre-registered to attend the one-day conference. Space is limited, so investment professionals interested in attending are encouraged to pre-register for the event. For more information or to pre-register, please visit www.westergaardsmallcap.com.

EVENT AT A GLANCE:

WHEN: Monday, November 6, 2006 from 8:00 A.M. to 5:30 P.M. ET

WHERE: Waldorf-Astoria Hotel
301 Park Avenue (Between 49th and 50th)
New York City

KEYNOTE
SPEAKER: Stephen Moore, senior economics writer for The Wall Street
Journal and economic commentator for CNBC TV. The author of four
books, including, most recently, "It's Getting Better All the
Time: The 100 Greatest Trends of the Last Century," Moore has
also served as a senior fellow in economics at the Cato
Institute, where he had published dozens of studies in federal
budget and tax policy. (Previously announced keynote speaker,
Lawrence Kudlow, will not be presenting, due to a conflict
related to reporting of the national elections.)

This year's conference will play host to companies scheduled to give multiple presentations throughout the day to small, informal groups of investment professionals. Confirmed presenting companies will include:


American Mold Guard, Inc. (NASDAQ:AMGI - News)
Ampex Corporation (NASDAQ:AMPX - News)
Ascent Solar Technologies, Inc. (NASDAQ:ASTI - News) (BSX: AKC)
AspenBio Pharma, Inc. (OTC BB:APNB.OB - News)
AVI BioPharma, Inc. (NASDAQ:AVII - News)
Baldwin Technology Co., Inc. (AMEX:BLD - News)
Charles & Colvard, Ltd. (NASDAQ:CTHR - News)
Chembio Diagnostic, Inc. (OTC BB:CEMI.OB - News)
Converted Organics, Inc. (Not Publicly Traded)
DayStar Technologies, Inc. (NASDAQ:DSTI - News)
DXP Enterprises, Inc. (NASDAQ:DXPE - News)
Elron Electronic Industries, Ltd. (NASDAQ:ELRN - News)
GigaBeam Corporation (NASDAQ:GGBM - News)
Green Plains Renewable Energy, Inc. (NASDAQ:GPRE - News)
Harbin Electric, Inc. (OTC BB:HRBN.OB - News)
ICOP Digital, Inc. (NASDAQ:ICOP - News) (NYSE Arca: ICOP)
INX, Inc. (NASDAQ:INXI - News)
Lumera Corporation (NASDAQ:LMRA - News)
Memry Corporation (AMEX:MRY - News)
MorphoSys AG (Frankfurt:MOR.F - News) (Prime Standard Segment, TecDAX)
Midway Gold Corp. (TSX VENTURE:MDW.V - News)
Nephros, Inc. (AMEX:NEP - News)
Neuralstem, Inc. (Not publicly traded)
Nymox Pharmaceutical Corporation (NASDAQ:NYMX - News)
QPC Lasers, Inc. (OTC BB:QPCI.OB - News)
Shumate Industries, Inc. (OTC BB:SHMT.OB - News)
Seabridge Gold, Inc. (AMEX:SA - News)
Taser International, Inc. (NASDAQ:TASR - News)
Universal Guardian Holdings, Inc. (OTC BB:UGHO.OB - News)
Vaughan Foods, Inc. (Not Publicly Traded)
To date, supporting corporate sponsors include:


Gold Level
Elite Financial Communications Group, LLC
RBC Dain Rauscher, Inc.

Silver Level
Capital IQ, Inc.
LANE PR
Research in Motion (BlackBerry)
Thomson Financial
ValueRich, Inc.
Vintage Filings, LLC
About Dutton Associates

Dutton Associates is one of the largest issuer-paid equity research firms in the United States and its investment performance is ranked comparable to that of the top Wall Street firms. Its analysts, primarily CFAs with over 20 years of experience at the major securities firms, are among the most experienced on Wall Street. The Company offers high-quality, independent, fundamental research on small cap public companies.

About Paulson Capital Corp.

Paulson Capital Corp. is the parent company to Paulson Investment Company, Inc. Located in Portland, Oregon, Paulson Investment Company, Inc. is the Northwest's largest independent brokerage firm and a national leader in public offerings of small and emerging growth companies with capital needs of $5 million to $45 million. Founded by Chet Paulson in 1970, it has managed or underwritten nearly 160 public and private offerings and has generated more than $1 billion for client companies.

Paulson Investment Company, Inc. was the managing underwriter for the initial and/or secondary public offerings for one or more of the companies affiliated with this conference. Paulson Investment Company, Inc. may make a market in one or more of the securities affiliated with this conference. These markets may, however, be changed at any time without notice. Individuals associated with Paulson Investment Company, Inc., and its officers and/or directors may hold shares in companies affiliated with this conference and may increase or decrease such holdings without notice. The contents of the presenting company's profiles on this site were prepared by Dutton Associates and are not to be construed as a solicitation to buy or sell any securities. Paulson Investment Company, Inc. does not warranty, guarantee or make any representations, or assume any liability with regard to financial results based on the use of information on this site.

This release may contain "forward-looking statements" based on current expectations but involving known and unknown risks and uncertainties. Actual results of achievements may be materially different from those expressed or implied. The Company's plan and objectives are based on judgments with respect to future conditions in the securities markets as well as general assumptions regarding the economy and competitive environment in the securities industry, which can be volatile and out of our control. In particular, we make assumptions about our ability to complete corporate finance transactions and increase the volume and size of our securities trading operations, which are difficult or impossible to predict accurately and often beyond the control of the Company. Therefore, there can be no assurance that any forward-looking statement will prove to be accurate.



Contact:
FOR MORE INFORMATION, PLEASE CONTACT:
Dodi Handy
President and CEO
Elite Financial Communications Group
407-585-1080
[e-mail]



--------------------------------------------------------------------------------
Source: Paulson Capital Corp.

[shmoopy38]

Lumera Corporation To Hold Conference Call To Discuss Q3 2006 Results

BOTHELL, Wash., Oct 30, 2006 (BUSINESS WIRE) -- Lumera Corporation (NASDAQ:LMRA), an emerging leader in the field of nanotechnology, will hold its quarterly conference call to discuss third quarter results on November 8, 2006 at 4:30 PM Eastern Standard Time (1:30 PM Pacific Standard Time).

Details to access the conference call and the live audio web cast are as follows:

Conference call

(Please call approximately ten minutes prior to the scheduled start of the call)

Toll-free: 800.798.2796

International callers: 617.614.6204

Pass code: 54143215

Live Audio web cast: www.Lumera.com

Replay and archive information:

(Telephone replay available until November 15, 2006)

Toll-free: 888-286-8010

International callers: 617-801-6888

Pass code: 56976581

Web cast will be archived on the Company's website at www.Lumera.com

About Lumera

Lumera is a leader in the emerging field of nanotechnology. The company designs proprietary molecular structures and polymer compounds for the bioscience and communications/computing industries, both of which represent large market opportunities. The company also has developed proprietary processes for fabricating such devices. For more information, please visit www.lumera.com.

SOURCE: Lumera Corporation

Lumera Corporation
Helene F. Jaillet (Investor Relations), 425-398-6546
or
The Summit Group Communications
Todd Wolfenbarger (Media), 801-595-1155
http://www.lumera.com

[psichedout]

I have been in and out of LMRA and am now back in. I like the company's product and you can swing trade this or go long...either way there is $$ to be made here.
Sue

[shmoopy38]

NANOTECH TSUNAMI COMING ALONG
Monday, October 23, 2006 - FreeMarketNews.com

"... an immense technical, business, and social tsunami is coming along shortly ... companies are already being forced to deal with a blinding rate of technological change. This speed-up will likely increase, and definitely spread." -Nanotechnology Now

[HeedTheCall]

Don't know but like your thoughts. Given the massive data their new wireless system can transmit and the success of the test I'd be incline to say once the dust settles a little and with a small pullback this stock is the place to be!

[Major_Bankz]

Could this be the next SDLI ? traded as high as $500 /share?